Michele Hornstein, DO
Family Medicine · Ocala, FLNPI 1972542256
Payments from drug & device makers
Across 354 payments — averaging $29.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- Novo Nordisk$1K
- AstraZeneca$1K
- Amgen$1K
- Lilly USA, LLC$651
- Lundbeck LLC$480
- plus $3K from 30 others
What the payments were for
- Food & beverage$10,17999%
- Education$1011%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 89 | $2,301 |
| Novo Nordisk | 59 | $1,427 |
| AstraZeneca | 24 | $1,379 |
| Amgen | 38 | $1,210 |
| Lilly USA, LLC | 34 | $651 |
| Lundbeck LLC | 6 | $480 |
| Biohaven Pharmaceuticals, Inc. | 6 | $298 |
| Novartis | 18 | $277 |
| GSK | 5 | $182 |
| Otsuka America Pharmaceutical, Inc. | 4 | $171 |
| Pfizer | 8 | $165 |
| Biohaven Pharmaceutical Holding Company Ltd. | 4 | $153 |
| Idorsia Pharmaceuticals US Inc | 2 | $143 |
| Eisai Inc. | 4 | $139 |
| Astellas Pharma US Inc | 5 | $139 |
| Boehringer Ingelheim | 7 | $120 |
| Sanofi-aventis U.S. LLC | 6 | $114 |
| C2n Diagnostics, LLC | 1 | $107 |
| E.r. Squibb & Sons, L.L.C. | 1 | $99 |
| Corium, LLC | 1 | $91 |
| Exact Sciences | 4 | $86 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 5 | $85 |
| Merck | 4 | $77 |
| Amarin Pharma, Inc. | 3 | $60 |
| Xeris Pharmaceuticals, Inc. | 3 | $59 |
| Bayer | 2 | $45 |
| Nestle Healthcare Nutrition Inc. | 2 | $37 |
| Philips North America LLC | 1 | $34 |
| Boston Scientific | 1 | $25 |
| Esperion Therapeutics, Inc. | 1 | $22 |
| Lexicon Pharmaceuticals, Inc. | 1 | $21 |
| Mylan Specialty L.p. | 1 | $20 |
| Teva Pharmaceuticals USA, Inc. | 1 | $18 |
| Biotronik Inc. | 1 | $18 |
| Johnson & Johnson | 1 | $17 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$10,280 in reported general payments places this provider in the 90th percentile of 7,282 family medicine providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 103 | $164,672 |
| JardianceEmpagliflozin | 91 | $100,900 |
| MounjaroTirzepatide | 59 | $69,233 |
| TrulicityDulaglutide | 36 | $68,087 |
| EliquisApixaban | 64 | $66,419 |
| VraylarCariprazine Hcl | 29 | $54,606 |
| XareltoRivaroxaban | 37 | $41,347 |
| LinzessLinaclotide | 30 | $38,879 |
| Repatha SureclickEvolocumab | 31 | $38,402 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 37 | $29,493 |
| RybelsusSemaglutide | 15 | $24,091 |
| GlyxambiEmpagliflozin/Linagliptin | 14 | $23,250 |
| JanuviaSitagliptin Phosphate | 14 | $22,954 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 19 | $21,418 |
| Lamictal XrLamotrigine | 12 | $20,268 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $1,427 | $188,762118 claims |
| Lilly USA, LLCMounjaro, Trulicity | $651 | $137,32195 claims |
| Boehringer IngelheimJardiance, Glyxambi | $120 | $124,149105 claims |
| AbbVieVraylar, Linzess, Synthroid | $2,301 | $98,058120 claims |
| PfizerEliquis | $165 | $66,41964 claims |
| Johnson & JohnsonXarelto | $17 | $41,34737 claims |
| AstraZenecaFarxiga, Symbicort | $1,379 | $24,66232 claims |
| MerckJanuvia | $77 | $22,95414 claims |
| GSKTrelegy Ellipta | $182 | $21,41819 claims |
| Astellas Pharma US IncMyrbetriq | $139 | $12,66014 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 7,282 family medicine providers in Florida.
Other family medicine in Ocala
- John NardandreaOcala$30.8M
- David OliverOcala$4.5M
- Hugh ColemanDaytona Beach$115.5M
- Alexander WhiteDaytona Beach$69.7M
- Ronald SurowitzJupiter$38.3M
- Bruce RankinDeland$36.7M
- Keila HooverMiami$33.7M
- Jorge CasoMiami$22.6M
- Sharrell CooperPalm Coast$16.9M
- Christopher GallowayMelbourne$15.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.